Intracerebral injection of low amounts of norharman induces moderate Parkinsonism-like behavioral symptoms in rat.
β-Carbolines (BCs) are considered to be endogenous toxins and have been proposed as possible causative candidates inducing Parkinson's disease (PD). However, there is controversy about the effect and also effective dose of these compounds in the etiology of PD. This study was designed to further examine the effect of norharman (NH), a BC which in mammalian brain occurs at high levels in the substantia nigra, on the development of Parkinsonism-like behaviors in rats. A small amount (4μl) of NH solution at 2 or 200ng/ml was unilaterally injected into either striatum or substantia nigra (SN) by stereotaxic surgery. The development of Parkinsonism was assessed by three conventional behavioral tests, compared to the effects of unilateral 6-hydroxydopamine (6-OHDA) - induced lesions in the nigrostriatal pathway. An apomorphine-induced rotational test revealed no Parkinsonism-like behavior in the NH treated groups. However, rats that received the high concentration of NH into their SN showed significant biased swings in the elevated body swing test. In a rotarod test, NH treated groups showed relatively weak motor performance and their learning patterns were close to that of the 6-OHDA treated rats. Considering that the rotational test is only valid in animals with severe Parkinsonism, but time spent on the rotating rod correlates inversely with severity of Parkinsonism, our results indicate that a single exposure to low amounts of NH is effective in producing moderate Parkinsonism-like behavioral symptoms, possibly through a neurotoxic effect of this agent on the SN dopaminergic neurons.
Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Mohammad Hossein
MH
Esmaeili
Mohadeseh
M
Movahedi
Ayda
A
Faraji
Hashem
H
Haghdoost-Yazdi
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002243:Carbolines; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006247:Harmine / Q000031:analogs & derivatives* / Q000633:toxicity; D007276:Injections, Intraventricular; D008297:Male; D009483:Neuropsychological Tests; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000503:physiopathology; D009498:Neurotoxins / Q000633:toxicity*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D045442:Rotarod Performance Test
D002243:Carbolines; D009498:Neurotoxins; D006247:Harmine; C010262:norharman